Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NET RETREAT
NCT05773274Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2024
- Primary completion
- Apr 2029
- Countries
- 2
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by National Cancer Institute. Started Jan 2024; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT05773274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05773274.